Evidence map›Paper›PMID 40564899›Full record

ArticleInternational journal of molecular sciences2025

Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study.

Eiji Hishinuma, Shogo Shigeta, Naomi Matsukawa, Yasunobu Okamura, Ikuko N Motoike, Takamichi Minato, Yusuke Shibuya, Jun Yasuda, Kengo Kinoshita, Seizo Koshiba and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eiji HishinumaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.
Shogo ShigetaDepartment of Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan.
Naomi MatsukawaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8573, Japan.
Yasunobu OkamuraAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.ORCID 0000-0001-9847-9037
Ikuko N MotoikeTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8573, Japan.
Takamichi MinatoDepartment of Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan.
Yusuke ShibuyaDepartment of Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan.
Jun YasudaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8573, Japan.ORCID 0000-0002-3887-6871
Kengo KinoshitaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.
Seizo KoshibaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.
Muneaki ShimadaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.ORCID 0000-0003-1826-6723

Funding

Japan Society for the Promotion of Science (JSPS) KAKENHI 20K18211Japan Society for the Promotion of Science (JSPS) KAKENHI 23K06688Japan Society for the Promotion of Science (JSPS) KAKENHI JP22H03219Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED JP24ama121019Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED JP24ama121038Tohoku Medical Megabank Project (Tohoku University) of the MEXT and the Japan Agency for Medical Research and Development JP21tm0124005
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is diagnosed at an advanced stage in over half of the patients and its prognosis remains unfavorable. CA125, one of the most frequent positive tumor markers in patients with EOC, has certain limitations. Therefore, more accurate clinical biomarkers are needed. Liquid biopsy with cancer related molecules, such as circulating tumor DNA, is a new option for cancer diagnosis and prognosis. We explored the potential of plasma metabolomic and proteomic analyses as novel monitoring methods for the patients with EOC. Of seven patients, six experienced disease recurrence or progression. CA125 plasma measurements were conducted for disease monitoring. Plasma metabolome and proteome analyses were performed using liquid chromatography-tandem mass spectrometry. Ten and four metabolome indicators were significantly increased and decreased in association with chemotherapeutic resistance, respectively. In addition, thirty-seven and nine proteins displayed high and low levels associated with chemotherapeutic resistance, respectively. Several metabolome pathways and protein concentrations corresponded to the clinical course of each patient. This pilot study suggested the potential of the assessment of metabolome and proteome analysis as a useful tool for developing novel monitoring biomarkers for patients with recurrent EOC.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialMetabolomeOvarian NeoplasmsProteomeAdultAgedCA-125 AntigenChromatography, LiquidFemaleHumansMetabolomicsMiddle AgedNeoplasm Recurrence, LocalPilot ProjectsPrognosisBiomarkers, TumorCA-125 AntigenProteomebiomarkercirculating tumor DNAepithelial ovarian cancermetabolomicsproteomics

Identifiers

PMID40564899
PMCPMC12192702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.